Sobenna George1, David R Weber1, Paige Kaplan1, Kelly Hummel1, Heather M Monk1, Michael A Levine1. 1. Division of General Pediatrics (S.G.), Division of Endocrinology and Diabetes (D.R.W., M.A.L.), Division of Genetics (P.K.), and Department of Pharmacy (K.H., H.M.M.), The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104; Department of Pediatrics (P.K., M.A.L.), University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104; and University of Rochester School of Medicine and Dentistry (D.R.W.), Rochester, New York 14642.
Abstract
CONTEXT: Zoledronic acid (ZA) is increasingly used in young patients with bone disorders. However, data related to the safety of ZA administration in this population are limited. OBJECTIVE: The study aimed to characterize the short-term safety profile of ZA and identify risk factors for ZA-related adverse events (AEs) in young patients. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective chart review of inpatients and outpatients less than 21 years old who received at least one ZA infusion between July 2010 and January 2014 at The Children's Hospital of Philadelphia. RESULTS: Eighty-one patients (56% male; median age, 12 y; age at first infusion, 0.5 to 20 y) with diverse skeletal disorders received a total of 204 infusions. The most common indications were osteoporosis (33% of cohort) and osteogenesis imperfecta (27.2%). The median ZA dose was 0.025 mg/kg (interquartile range, 0.025-0.05); the median dosing interval was 6 months (range, 1 to 25.6 mo). AEs were mild and more common after the first ZA infusion in patients with no previous bisphosphonate exposure: hypophosphatemia (25.2% of infusions), acute phase reactions (19.1%), and hypocalcemia (16.4%). Symptomatic hypocalcemia requiring iv calcium occurred after two infusions. ZA dose was significantly associated with hypophosphatemia, but not other AEs. Hypocalcemia was more common in patients with high bone turnover as assessed by preinfusion alkaline phosphatase levels. AEs were not associated with diagnosis, baseline serum calcium, or calcium/calcitriol supplementation. CONCLUSION: Acute AEs related to ZA infusion in youths are common, occur principally after the first ZA infusion in bisphosphonate-naive patients, and are typically mild and easily managed. Future prospective studies are needed to determine the potential long-term risks, as well as benefits, of ZA therapy in the pediatric population.
CONTEXT: Zoledronic acid (ZA) is increasingly used in young patients with bone disorders. However, data related to the safety of ZA administration in this population are limited. OBJECTIVE: The study aimed to characterize the short-term safety profile of ZA and identify risk factors for ZA-related adverse events (AEs) in young patients. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective chart review of inpatients and outpatients less than 21 years old who received at least one ZA infusion between July 2010 and January 2014 at The Children's Hospital of Philadelphia. RESULTS: Eighty-one patients (56% male; median age, 12 y; age at first infusion, 0.5 to 20 y) with diverse skeletal disorders received a total of 204 infusions. The most common indications were osteoporosis (33% of cohort) and osteogenesis imperfecta (27.2%). The median ZA dose was 0.025 mg/kg (interquartile range, 0.025-0.05); the median dosing interval was 6 months (range, 1 to 25.6 mo). AEs were mild and more common after the first ZA infusion in patients with no previous bisphosphonate exposure: hypophosphatemia (25.2% of infusions), acute phase reactions (19.1%), and hypocalcemia (16.4%). Symptomatic hypocalcemia requiring iv calcium occurred after two infusions. ZA dose was significantly associated with hypophosphatemia, but not other AEs. Hypocalcemia was more common in patients with high bone turnover as assessed by preinfusion alkaline phosphatase levels. AEs were not associated with diagnosis, baseline serum calcium, or calcium/calcitriol supplementation. CONCLUSION: Acute AEs related to ZA infusion in youths are common, occur principally after the first ZA infusion in bisphosphonate-naive patients, and are typically mild and easily managed. Future prospective studies are needed to determine the potential long-term risks, as well as benefits, of ZA therapy in the pediatric population.
Authors: Ian R Reid; Kenneth Lyles; Guoqin Su; Jacques P Brown; John P Walsh; Javier del Pino-Montes; Paul D Miller; William D Fraser; Susan Cafoncelli; Christina Bucci-Rechtweg; David J Hosking Journal: J Bone Miner Res Date: 2011-09 Impact factor: 6.741
Authors: Alexandre T Assaf; Ralf Smeets; Björn Riecke; Eva Weise; Alexander Gröbe; Marco Blessmann; Tim Steiner; Johannes Wikner; Reinhard E Friedrich; Max Heiland; Frank Hoelzle; Frank Gerhards Journal: Anticancer Res Date: 2013-09 Impact factor: 2.480
Authors: Craig F Munns; Mansoor H Rajab; Janet Hong; Julie Briody; Wolfgang Högler; Mary McQuade; David G Little; Christopher T Cowell Journal: Bone Date: 2007-05-13 Impact factor: 4.398
Authors: Amna Ibrahim; Nancy Scher; Grant Williams; Rajeshwari Sridhara; Ning Li; Gang Chen; John Leighton; Brian Booth; Jogarao V S Gobburu; Atiqur Rahman; Yung Hsieh; Rebecca Wood; Debra Vause; Richard Pazdur Journal: Clin Cancer Res Date: 2003-07 Impact factor: 12.531